Rallybio Corp. (RLYB)
16.70
-0.18
(-1.04%)
USD |
NASDAQ |
Sep 14, 11:06
Rallybio Enterprise Value : -3.295M for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | -3.295M |
| September 10, 2026 | -3.958M |
| September 09, 2026 | -2.791M |
| September 08, 2026 | -4.701M |
| September 04, 2026 | -3.030M |
| September 03, 2026 | -3.295M |
| September 02, 2026 | -2.950M |
| September 01, 2026 | -4.277M |
| August 31, 2026 | -3.746M |
| August 28, 2026 | -3.64M |
| August 27, 2026 | -3.905M |
| August 26, 2026 | -3.268M |
| August 25, 2026 | -3.242M |
| August 24, 2026 | -3.693M |
| August 21, 2026 | -3.534M |
| August 20, 2026 | -4.754M |
| August 19, 2026 | -2.632M |
| August 18, 2026 | -3.852M |
| August 17, 2026 | -2.632M |
| August 14, 2026 | -2.685M |
| August 13, 2026 | -2.844M |
| August 12, 2026 | -4.808M |
| August 11, 2026 | -5.922M |
| August 10, 2026 | -4.701M |
| August 07, 2026 | -7.090M |
| Date | Value |
|---|---|
| August 06, 2026 | -6.930M |
| August 05, 2026 | -7.196M |
| August 04, 2026 | -8.151M |
| August 03, 2026 | -8.204M |
| July 31, 2026 | -8.310M |
| July 30, 2026 | -7.567M |
| July 29, 2026 | -8.151M |
| July 28, 2026 | -7.116M |
| July 27, 2026 | -6.294M |
| July 24, 2026 | -6.294M |
| July 23, 2026 | -5.869M |
| July 22, 2026 | -4.648M |
| July 21, 2026 | -3.109M |
| July 20, 2026 | -4.171M |
| July 17, 2026 | -5.710M |
| July 16, 2026 | -8.151M |
| July 15, 2026 | -7.249M |
| July 14, 2026 | -7.886M |
| July 13, 2026 | -8.522M |
| July 10, 2026 | -9.372M |
| July 09, 2026 | -8.841M |
| July 08, 2026 | -9.637M |
| July 07, 2026 | -9.690M |
| July 06, 2026 | -9.424M |
| July 02, 2026 | -8.920M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Beam Therapeutics, Inc. | 1.572B |
| C4 Therapeutics, Inc. | 234.59M |
| Cullinan Therapeutics, Inc. | 996.62M |
| Q32 Bio, Inc. | 162.50M |
| Arrowhead Pharmaceuticals, Inc. | 11.47B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 43.66M |
| Total Expenses (Quarterly) | -43.66M |
| EPS Diluted (Quarterly) | 7.531 |
| Earnings Yield | 46.78% |
| Normalized Earnings Yield | 14.84 |